Inventor · disambiguated record
Matthew Rein Scholz
Also filed as: SCHOLZ MATTHEW R · SCHOLZ MATTHEW REIN
6 granted patents·15 pending applications·8 citations·filing 2011–2025
75Inventor score
Files withOISIN BIOTECHNOLOGIES INC9IMMUSOFT CORP8OISIN BIOTECHNOLOGIES2SCHOLZ MATTHEW REIN1SIGMA GENETICS INC1
Top patents by PatentIndex Score
21 records- 0180US11603543B2Fusogenic lipid nanoparticles for target cell-specific production of a therapeutic proteinOISIN BIOTECHNOLOGIES INC·Filed 2019·Granted Mar 14, 2023·2 cites·28 claims
- 0277US11352603B2Methods for in vitro memory B cell differentiation and transduction with VSV-G pseudotyped viral vectorsIMMUSOFT CORP·Filed 2019·Granted Jun 7, 2022·1 cites·18 claims
- 0376US2024382623A1Systems and methods for the targeted production of a therapeutic protein within a target cellOISIN BIOTECHNOLOGIES INC·Filed 2024·Application pending·0 cites
- 0473US2024374760A1Compositions and methods for liver-specific expression of follistatinOISIN BIOTECHNOLOGIES INC·Filed 2024·Application pending·0 cites
- 0572US2023348937A1Fusogenic lipid nanoparticles for target cell-specific production of a therapeutic protein fusogenic lipid nanoparticles and methods of manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a diseaseOISIN BIOTECHNOLOGIES INC·Filed 2022·Application pending·0 cites
- 0671US10240125B2Methods for in vitro memory B cell differentiation and transduction with VSV-G pseudotyped viral vectorsIMMUSOFT CORP·Filed 2014·Granted Mar 26, 2019·1 cites·14 claims
- 0771US2023013198A1Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectorsIMMUSOFT CORP·Filed 2022·Application pending·0 cites
- 0868US11525146B2Expression constructs, fusogenic lipid-based nanoparticles and methods of use thereofOISIN BIOTECHNOLOGIES INC·Filed 2018·Granted Dec 13, 2022·1 cites·27 claims
- 0968US9074223B2Vectors and methods for transducing B cellsSCHOLZ MATTHEW REIN·Filed 2011·Granted Jul 7, 2015·3 cites·15 claims
- 1066US2025243459A1Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectorsIMMUSOFT CORP·Filed 2025·Application pending·0 cites
- 1166US2023220422A1Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease, condition, or disorder associated with a target cellOISIN BIOTECHNOLOGIES INC·Filed 2022·Application pending·0 cites
- 1265US2020009268A1Expression constructs and systems for systemic and non-specific in vivo delivery of a nucleic acid to human cells and transient target cell-specific production of a therapeutic proteinOISIN BIOTECHNOLOGIES INC·Filed 2019·Application pending·0 cites
- 1363US2023081163A1B cells for in vivo delivery of therapeutic agentsIMMUSOFT CORP·Filed 2022·Application pending·0 cites
- 1462US2025346925A1Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a diseaseOISIN BIOTECHNOLOGIES INC·Filed 2025·Application pending·0 cites
- 1559US2016051700A1Systems and methods for the targeted production of a therapeutic protein within a target cellOISIN BIOTECHNOLOGIES·Filed 2014·Application pending·0 cites
- 1653US2022106608A1Fusogenic lipid nanoparticles for the target cell-specific production of rapamycin inducible therapeutic proteinsOISIN BIOTECHNOLOGIES INC·Filed 2021·Application pending·0 cites
- 1753US2016010110A1Systems and methods for the targeted production of a therapeutic protein within a target cellOISIN BIOTECHNOLOGIES·Filed 2015·Application pending·0 cites
- 1845US2021047619A1B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strengthIMMUSOFT CORP·Filed 2019·Application pending·0 cites
- 1943US2022193129A1B cells for in vivo delivery of therapeutic agents and dosages thereofIMMUSOFT CORP·Filed 2018·Application pending·0 cites
- 2043US2018002664A1B cells for in vivo delivery of therapeutic agentsIMMUSOFT CORP·Filed 2015·Application pending·0 cites
- 2141US11442117B2Systems, devices, and methods for electroporation induced by magnetic fieldsSIGMA GENETICS INC·Filed 2019·Granted Sep 13, 2022·0 cites·16 claims
Join the waitlist — get patent alerts
Get an alert when Matthew Rein Scholz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →